A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin

Journal of Chemotherapy

Volumn 26, Issue 4, 2014, Pages 243-247

  He, Shengli ^a   Shen, Jie ^a   Sun, Xianjun ^a   Liu, Luming ^a   Dong, Jingcheng ^b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biliary tract cancer; Cisplatin; FOLFOX 4; Gemcitabine; Second line

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; CLINICAL ARTICLE; CONSTIPATION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIPHORA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; BILIARY TRACT NEOPLASMS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84903381897     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000133     Document Type: Article

References (27)

1. Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20:146-59.
2. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57:647-53.
3. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849-55.
4. Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006;106:361-5.
5. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02 Trial Investigators). N Engl J Med. 2010;362:1273-81.
6. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469-74.
7. Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology. 2009;76:254-61.
8. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A phase P study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2012;48:196-201.
9. Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, et al. Phase P study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs. 2011;29:1066-72.
10. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs. 2012;30:708-13.
11. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50-5.
12. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010; 11:1142-8.
13. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliarytumours. Eur J Cancer. 1995; 31:1594-8.
14. Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase P study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543-8.
15. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
16. Novarino AM, Satolli MA, Chiappino I, Giacobino A, Napoletano R, Ceccarelli M, et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer. Am J Clin Oncol. 2012;9 (abstract: PMID: 22781390).
17. Kautio AL, Haanpää M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapyinduced peripheral neuropathy. Anticancer Res. 2011;31:3493-6.
18. Simon R. How large should a phase P trial of a new drug be? Cancer Treat Rep. 1987;71:1079-85.
19. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeox yglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11:48-54.
20. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181-8.
21. Katayose Y, Ohtsuka H, Kitamura Y, Masuda K, Nakagawa K, Yamamoto K, et al. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. Hepatogastroenterology. 2012;59:691-5.
22. Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, et al. Phase P Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17:13.
23. Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, et al. Imatinibmesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase P study. Onkologie. 2011;34:469-70.
24. He XR, Wu XP. Difference in biological characteristics and sensitivity to chemotherapy and radiotherapy between intrahepatic and extrahepatic cholangiocarcinoma cells in vitro. Chin Med Sci J. 2008;23:54-9.
25. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentrerandomised phase II study-The UK ABC-01 Study. Br J Cancer. 2009;101:621-7.
26. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332-8.
27. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13:181-8.